Literature DB >> 11893131

Does breast tumor location influence success of sentinel lymph node biopsy?

Gretchen M Ahrendt1, Prakash Laud, Judy Tjoe, Dan Eastwood, Alonzo P Walker, Mary F Otterson, Philip N Redlich.   

Abstract

BACKGROUND: Controversy exists regarding the influence of sentinel lymph node (SLN) mapping technique or patient variables on the success rate of SLN mapping. We undertook a prospective study in a single institution series to evaluate multiple variables that could adversely affect SLN identification rates. STUDY
DESIGN: Data were collected on 174 patients who underwent 177 SLN mapping procedures followed by axillary dissection from October 1996 through January 2000. Patient demographics, body mass index (BMI), biopsy method, tumor size, palpability, and location were recorded. SLNs were identified by blue dye only (n = 31), Tc-99m sulfur colloid only (n = 34), or combined techniques (n = 112). Data were analyzed by logistic regression analysis and expressed as the probability of failure to map the SLN.
RESULTS: SLNs were identified successfully in 150 of 177 procedures (85%) with a false negative rate of 3.7%. Mapping success reached 93% using combination blue dye and isotope. Variables found to adversely affect SLN mapping success and the odds ratio of failure (OR) included lower inner quadrant (LIQ) location (OR 35.6), blue dye only (OR 42.4), BMI >30 and upper outer quadrant (UOQ) location (OR 14.6), and nonpalpable UIQ location (OR 25). LIQ location adversely affects mapping success independent of technique, tumor size, or obesity. Obesity and nonpalpability were adverse factors when tumors were located in the UOQ and UIQ, respectively. Age, biopsy technique, and tumor diameter did not affect SLN mapping success.
CONCLUSIONS: SLN mapping success is influenced by technique and tumor location, with best results achieved using combined techniques and for lesions located in quadrants other than the LIQ. Obesity and tumor palpability influence success in the context of tumor location.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893131     DOI: 10.1016/s1072-7515(01)01174-7

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  9 in total

1.  Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa S Flippo-Morton; Henry M Kuerer; Monet Bowling; Kelly K Hunt
Journal:  Ann Surg       Date:  2015-03       Impact factor: 12.969

2.  Results of preoperative lymphoscintigraphy for breast cancer are predictive of identification of axillary sentinel lymph nodes.

Authors:  Frédéric Marchal; Philippe Rauch; Olivier Morel; Jean Claude Mayer; Pierre Olivier; Agnès Leroux; Jean Luc Verhaeghe; François Guillemin
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

3.  Impact of axillary nodal metastases on lymphatic mapping and sentinel lymph node identification rate in patients with early stage breast cancer.

Authors:  Ettore Pelosi; Ada Ala; Marilena Bellò; Anastasios Douroukas; Giuseppe Migliaretti; Ester Berardengo; Teresio Varetto; Riccardo Bussone; Gianni Bisi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-19       Impact factor: 9.236

4.  Identification of metastatic nodal disease in a phase 1 dose-escalation trial of intraoperative sentinel lymph node mapping in non-small cell lung cancer using near-infrared imaging.

Authors:  Denis M Gilmore; Onkar V Khullar; Michael T Jaklitsch; Lucian R Chirieac; John V Frangioni; Yolonda L Colson
Journal:  J Thorac Cardiovasc Surg       Date:  2013-06-19       Impact factor: 5.209

5.  99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer.

Authors:  Hiroyuki Takei; Kimito Suemasu; Masafumi Kurosumi; Jun Ninomiya; Yoshio Horii; Kenichi Inoue; Toshio Tabei
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

6.  Impact of Tumor Localization and Method of Preoperative Biopsy on Sentinel Lymph Node Mapping After Periareolar Nuclide Injection.

Authors:  Julia Krammer; Anja Dutschke; Clemens G Kaiser; Andreas Schnitzer; Axel Gerhardt; Julia C Radosa; Joachim Brade; Stefan O Schoenberg; Klaus Wasser
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

7.  Real-time sentinel lymph node biopsy guidance using combined ultrasound, photoacoustic, fluorescence imaging: in vivo proof-of-principle and validation with nodal obstruction.

Authors:  Jeeun Kang; Jin Ho Chang; Sun Mi Kim; Hak Jong Lee; Haemin Kim; Brian C Wilson; Tai-Kyong Song
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

8.  A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.

Authors:  Tian Wang; Yuanjing Hu; Ya He; Peisong Sun; Zhengchen Guo
Journal:  Arch Gynecol Obstet       Date:  2019-02-12       Impact factor: 2.344

Review 9.  The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review.

Authors:  Pei-Sheng He; Feng Li; Guan-Hua Li; Can Guo; Tian-Jin Chen
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.